Vincentius Smit
Hoogleraar Klinische Pathologie
- Naam
- Prof.dr. V.T.H.B.M. Smit
- Telefoon
- +31 71 526 6622
- v.t.h.b.m.smit@lumc.nl
- ORCID iD
- 0000-0003-3730-5652
Vincent Smit is hoogleraar pathologie, afdelings hoofd en opleider Pathologie van het Leids Universitair Medisch Centrum (LUMC).
Vincent Smit is hoogleraar pathologie, afdelings hoofd en opleider Pathologie van het Leids Universitair Medisch Centrum (LUMC).
Wetenschappelijke carrière
Vincent Smit heeft zijn opleiding Geneeskunde en zijn promotieonderzoek gedaan aan de Universiteit van Leiden. De titel van zijn proefschrift (1991) luidt ‘Genetic analysis of solid tumors at different levels of genomic organization’. Vervolgens specialiseerde Smit zich verder in de oncologische pathologie in het bijzonder de gynecopathologie en de mammapathologie Hij werd in mei 2013 benoemd tot hoogleraar Pathologie van het Leids Universiteit Medisch Centrum en tevens afdelingshoofd. De titel van zijn oratie is ‘Een kwestie van de juiste stip’.
Hoogleraar Klinische Pathologie
- Faculteit Geneeskunde
- Divisie 4
- Pathologie
- Helderman, N.C.; Andini, K.D.; Leerdam, M.E. van; Hest, L.P. van; Hoekman, D.R.; Ahadova, A.; Bajwa-ten Broeke, S.W.; Bosse, T.; Logt, E.M.J. van der; Imhann, F.; Kloor, M.; Langers, A.M.J.; Smit, V.T.H.B.M.; Terlouw, D.; Wezel, T. van; Morreau, H. & Nielsen, M. (2024), MLH1 promotor hypermethylation in colorectal and endometrial carcinomas from patients with Lynch syndrome, The Journal of Molecular Diagnostics 26(2): 106-114.
- Volinsky-Fremond, S.; Horeweg, N.; Andani, S.; Wolf, J.B.; Lafarge, M.W.; Kroon, C.D. de; Ortoft, G.; Hogdall, E.; Dijkstra, J.; Jobsen, J.J.; Lutgens, L.C.H.W.; Powell, M.E.; Mileshkin, L.R.; Mackay, H.; Leary, A.; Katsaros, D.; Nijman, H.W.; Boer, S.M. de; Nout, R.A.; Bruyn, M. de; Church, D.; Smit, V.T.H.B.M.; Creutzberg, C.L.; Koelzer, V.H. & Bosse, T. (2024), Author correction: prediction of recurrence risk in endometrial cancer with multimodal deep learning , Nature Medicine 30.
- Volinsky-Fremond, S.; Horeweg, N.; Andani, S.; Wolf, J.B.; Lafarge, M.W.; Kroon, C.D. de; Ortoft, G.; Hogdall, E.; Dijkstra, J.; Jobsen, J.J.; Lutgens, L.C.H.W.; Powell, M.E.; Mileshkin, L.R.; Mackay, H.; Leary, A.; Katsaros, D.; Nijman, H.W.; Boer, S.M. de; Nout, R.A.; Bruyn, M. de; Church, D.; Smit, V.T.H.B.M.; Creutzberg, C.L.; Koelzer, V.H. & Bosse, T. (2024), Prediction of recurrence risk in endometrial cancer with multimodal deep learning, Nature Medicine.
- Wakkerman, F.C.; Wu, J.Q.; Putter, H.; Juergenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Haverkort, M.A.D.; Jong, M.A. de; Mens, J.W.M.; Wortman, B.G.; Nout, R.A.; Leon-Castillo, A.; Powell, M.E.; Mileshkin, L.R.; Katsaros, D.; Alfieri, J.; Leary, A.; Singh, N.; Boer, S.M. de; Nijman, H.W.; Smit, V.T.H.B.M.; Bosse, T.; Koelzer, V.H.; Creutzberg, C.L. & Horeweg, N. (2024), Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer, The Lancet Oncology 25(6): 779-789.
- Kaya, M.; Post, C.C.B.; Tops, C.M.; Nielsen, M.; Crosbie, E.J.; Leary, A.; Mileshkin, L.R.; Han, K.T.Y.; Bessette, P.; Boer, S.M. de; Jürgenliemk-Schulz, I.M.; Lutgens, L.; Jobsen, J.J.; Haverkort, M.A.D.; Nout, R.A.; Kroep, J.; Creutzberg, C.L.; Smit, V.T.H.B.M.; Horeweg, N.; Wezel, T. van & Bosse, T. (2024), Molecular and clinicopathologic characterization of mismatch repair-deficient endometrial carcinoma not related to MLH1 promoter hypermethylation, Modern Pathology 37(3).
- Fremond, S.; Andani, S.; Wolf, J.B.; Dijkstra, J.; Melsbach, S.; Jobsen, J.J.; Brinkhuis, M.; Roothaan, S.; Jurgenliemk-Schulz, I.; Lutgens, L.C.H.W.; Nout, R.A.; Steen-banasik, E.M. van der; Boer, S.M. de; Powell, M.E.; Singh, N.; Mileshkin, L.R.; Mackay, H.J.; Leary, A.; Nijman, H.W.; Smit, V.T.H.B.M.; Creutzberg, C.L.; Horeweg, N.; Koelzer, V.H. & Bosse, T. (2023), Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts, The Lancet Digital Health 5(2): e71-e82.
- Kramer, C.J.H.; Lanjouw, L.; Ruano, D.; Elst, A. ter; Santandrea, G.; Solleveld-Westerink, N.; Werner, N.; Hout, A.H. van der; Kroon, C.D. de; Wezel, T. van; Berger, L.P.; Jalving, M.; Wesseling, J.; Smit, V.T.H.B.M.; Bock, G.H. de; Asperen, C.J. van; Mourits, M.J.E.; Vreeswijk, M.P.G.; Bart, J. & Bosse, T. (2023), Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas, The Journal of Pathology 262(2).
- Kaya, M.; Jobsen, J.; Rutten, T.; Vermij, L.; Oosting, J.; Creutzberg, C.; Smit, V.; Parra-Herran, C.; Nucci, M.; Horeweg, N. & Bosse, T. (2023), Prognostic Relevance and Reproducibility of Pattern-Based Immune Scoring in Endometrial Carcinoma, Laboratory Investigation 103(3): S926-S927.
- Heerik, A.S.V.M. van den; Haar, N.T. ter; Vermij, L.; Jobsen, J.J.; Brinkhuis, M.; Roothaan, S.M.; Leon-Castillo, A.; Ortoft, G.; Hogdall, E.; Hogdall, C.; Wezel, T. van; Lutgens, L.C.H.W.; Haverkort, M.A.D.; Khattra, J.; McAlpine, J.N.; Creutzberg, C.L.; Smit, V.T.H.B.M.; Gilks, C.B.; Horeweg, N. & Bosse, T. (2023), QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction, JCO Global Oncology 9.
- Horeweg, N.; Nout, R.A.; Jürgenliemk-Schulz, I.M.; Lutgens, L.C.H.W.; Jobsen, J.J.; Haverkort, M.A.D.; Mens, J.W.M.; Slot, A.; Wortman, B.G.; Boer, S.M. de; Stelloo, E.; Verhoeven-Adema, K.W.; Putter, H.; Smit, V.T.H.B.M.; Bosse, T.; Creutzberg, C.L. & PORTEC Study Grp (2023), Molecular classification predicts response to radiotherapy in the randomized PORTEC-1 and PORTEC-2 trials for early-stage endometrioid endometrial cancer, Journal of Clinical Oncology 41(27): 4369-+.
- Vermij, L.; Jobsen, J.J.; Leon-Castillo, A.; Brinkhuis, M.; Roothaan, S.; Powell, M.E.; Boer, S.M. de; Khaw, P.; Mileshkin, L.R.; Fyles, A.; Leary, A.; Genestie, C.; Jnrgenliemk-Schulz, I.M.; Crosbie, E.J.; Mackay, H.J.; Nijman, H.W.; Nout, R.A.; Smit, V.T.H.B.M.; Creutzberg, C.L.; Horeweg, N.; Bosse, T.; Boer, S.M. de & TransPORTEC Consortium (2023), Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry, British Journal of Cancer 128(7): 1360-1368.
- Vermij, L.; Putter, H.; Jobsen, J.; Powell, M.; Boer, S. de; Leary, A.; Fyles, A.; Khaw, P.; Lutgens, L.; Jürgenliemk-Schulz, I.; Jong, M. de; Haverkort, D.; Nout, R.; Smit, V.; Steyerberg, E.; Bosse, T.; Creutzberg, C. & Horeweg, N. (2023), Development of an evidence-based adjuvant treatment decision support tool for endometrial cancer, Radiotherapy & Oncology 182: S484-S486.
- Bosse, T.; Creutzberg, C.L.; Crosbie, E.J.; Han, K.; Horeweg, N.; Leary, A.; Kroep, J.R.; McAlpine, J.N.; Powell, M.E.; Blanc-Durand, F.; Bruyn, M. de; Church, D.N.; Koelzer, V.H.; Kommoss, S.; Singh, N.; Bardet, A.; Counsell, N.; Putter, H.; Tu, D.; Edmondson, R.; Gordon, C.; Ledermann, J.; Morice, P.; MacKay, H.; Nijman, H.; Nout, R.A.; Smit, V.T.H.B.M.; White, H.; Alexandre, J.; Boer, S.M. de; Boere, I.; Cooper, R.; Ethier, J.L.; Frenel, J.S.; McGrane, J.; Taylor, A.; Welch, S.; Westermann, A.M.; Linden, H.D. van der; Farrelly, L.; Feeney, A.; Kaya, M.; Liu, W.; Melis, A.; Ngadjeua-Tchouatieu, F.; Parulekar, W.; Verhoeven-Adema, K. & RAINBO Res Consortium (2023), Refining adjuvant treatment in endometrial cancer based on molecular features, International Journal of Gynecological Cancer 33(1): 109-117.
- Kaya, M.; Horeweg, N.; Leary, A.; Welch, S.; Kommoss, S.; Weidner, N.; Fanfani, F.; Lorusso, D.; McGrane, J.; Gorp, T. van; Boere, I.; Westermann, A.M.; Heijns, J.B.; Putter, H.; Verhoeven-Adema, K.; Smit, V.T.H.B.M.; Creutzberg, C.L.; Bosse, T. & Kroep, J.R. (2023), The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN142): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer, Journal of Clinical Oncology 41(16).
- Aiyer, K.T.S.; Doeleman, T.; Ryan, N.A.; Nielsen, M.; Crosbie, E.J.; Smit, V.T.H.B.M.; Morreau, H.; Goeman, J.J. & Bosse, T. (2022), Validity of a two-antibody testing algorithm for mismatch repair deficiency testing in cancer, Modern Pathology 35(12).
- Vermij, L.; Leon-Castillo, A.; Singh, N.; Powell, M.E.; Edmondson, R.J.; Genestie, C.; Khaw, P.; Pyman, J.; McLachlin, C.M.; Ghatage, P.; Boer, S.M. de; Nijman, H.W.; Smit, V.T.H.B.M.; Crosbie, E.J.; Leary, A.; Creutzberg, C.L.; Horeweg, N.; Bosse, T. & TransPORTEC Consortium (2022), p53 immunohistochemistry in endometrial cancer, Modern Pathology 35(10): 1475-1483.
- Heerik, A.S.V.M.V.; Aiyer, K.T.S.; Stelloo, E.; Juergenliemk-Schulz, I.M.; Lutgens, L.C.H.W.; Jobsen, J.J.; Mens, J.W.M.; Steen-banasik, E.M. van der; Creutzberg, C.L.; Smit, V.T.H.B.M.; Horeweg, N. & Bosse, T. (2022), Microcystic elongated and fragmented (MELF) pattern of invasion, Gynecologic Oncology 166(3): 530--537.
- Wu, J.Q.; Horeweg, N.; Bruyn, M. de; Nout, R.A.; Jurgenliemk-Schulz, I.M.; Lutgens, L.C.H.W.; Jobsen, J.J.; Steen-Banasik, E.M. van der; Nijman, H.W.; Smit, V.T.H.B.M.; Bosse, T.; Creutzberg, C.L. & Koelzer, V.H. (2022), Automated causal inference in application to randomized controlled clinical trials, Nature Machine Intelligence 4(5): 436-+.
- Fremond, S.; Andani, S.; Wolf, J.B.; Dijkstra, J.; Jobsen, J.; Brinkhuis, M.; Roothaan, S.; Jurgenliemk-Schulz, I.; Lutgens, L.; Nout, R.; Steen-Banasik, E. van der; Boer, S. de; Powell, M.; Singh, N.; Mileshkin, L.; Mackay, H.; Leary, A.; Nijman, H.; Smit, V.; Creutzberg, C.; Horeweg, N.; Kolzer, V. & Bosse, T. (2022), AIRMEC - an Artificial Intelligence Model to Predict the Molecular Endometrial Cancer Classification from H&E Images, Laboratory Investigation 102(SUPPL 1): 746-747.
- Leon-Castillo, A.; Horeweg, N.; Peters, E.E.M.; Rutten, T.; Haar, N. ter; Smit, V.T.H.B.M.; Kroon, C.D.; Boennelycke, M.; Hogdall, E.; Hogdall, C.; Nout, R.R.A.; Creutzberg, C.L.; Ortoft, G. & Bosse, T. (2022), Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment, Gynecologic Oncology 164(3).
- Horeweg, N.; Workel, H.H.; Loiero, D.; Church, D.N.; Vermij, L.; Leon-Castillo, A.; Krog, R.T.; Boer, S.M. de; Nout, R.A.; Powell, M.E.; Mileshkin, L.R.; MacKay, H.; Leary, A.; Singh, N.; Jurgenliemk-Schulz, I.M.; Smit, V.T.H.B.M.; Creutzberg, C.L.; Koelzer, V.H.; Nijman, H.W.; Bosse, T. & Bruyn, M. de (2022), Tertiary lymphoid structures critical for prognosis in endometrial cancer patients, Nature Communications 13(1).
- Post, C.C.B.; Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, N.P.B.; Ledermann, J.A.; Khaw, P.; D'Amico, R.; Fyles, A.; Baron, M.H.; Kitchener, H.C.; Nijman, H.W.; Lutgens, L.C.H.W.; Brooks, S.; Jurgenliemk-Schulz, I.M.; Feeney, A.; Goss, G.; Fossati, R.; Ghatage, P.; Leary, A.; , V. do; Lissoni, A.A.; McCormack, M.; Nout, R.A.; Verhoeven-Adema, K.W.; Smit, V.T.H.B.M.; Putter, H. & Creutzberg, C.L. (2021), Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial, International Journal of Radiation Oncology - Biology - Physics 109(4): 975-986.
- Jonge, M.M. de; Kroon, C.D. de; Jenner, D.J.; Oosting, J.; Hullu, J.A. de; Mourits, M.J.E.; Garcia, E.B.G.; Ausems, M.G.E.M.; Collee, J.M.; Engelen, K. van; Beek, I. van de; Group, H.; Smit, V.T.H.B.M.; Rookus, M.A.; Bock, G.H. de; Leeuwen, F.E. van; Bosse, T.; Dekkers, O.M. & Asperen, C.J. van (2021), Endometrial cancer risk in women with germline BRCA1 or BRCA2 mutations, Journal of the National Cancer Institute 113(9): 1203-1211.
- Vermij, L.; Singh, N.; Leon-Castillo, A.; Horeweg, N.; Oosting, J.; Carlson, J.; Smit, V.; Gilks, B. & Bosse, T. (2021), Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer, Histopathology 79(4): 533-543.
- Boennelycke, M.; Peters, E.E.M.; Leon-Castillo, A.; Smit, V.T.H.B.M.; Bosse, T.; Christensen, I.J.; Ortoft, G.; Hogdall, C. & Hogdall, E. (2021), Prognostic impact of histological review of high-grade endometrial carcinomas in a large Danish cohort, Virchows Archiv 479(3): 507-514.
- Post, C.; Stelloo, E.; Smit, V.; Ruano, D.; Tops, C.M.; Vermij, L.; Rutten, T.A.; Jurgenliemk-Schulz, I.M.; Lutgens, L.C.; Jobsen, J.J.; Nout, R.A.; Crosbie, E.J.; Powell, M.E.; Mileshkin, L.; Leary, A.; Bessette, P.; Boer, S.M. de; Horeweg, N.; Wezel, T. van; Bosse, T. & Creutzberg, C.L. (2020), Prevalence and prognosis of Lynch syndrome and sporadic mismatch repair deficiency in the combined portec-1,-2 and-3 endometrial cancer trials, International Journal of Gynecological Cancer 30: A20-A20.
- Tesfai, F.M.; Kroep, J.R.; Gaarenstroom, K.; Kroon, C. de; Loenhout, R. van; Smit, V.; Trimbos, B.; Nout, R.A.; Poelgeest, M.I.E. van & Beltman, J.J. (2020), Fertility-sparing surgery of cervical cancer >2 cm (International Federation of Gynecology and Obstetrics 2009 stage IB1-IIA) after neoadjuvant chemotherapy, International Journal of Gynecological Cancer 30(1): 115-121.
- Vermij, L.; Smit, V.; Nout, R. & Bosse, T. (2020), Incorporation of molecular characteristics into endometrial cancer management, Histopathology 76(1): 52-63.
- Vermij, L.; Horeweg, N.; Leon-Castillo, A.; Rutten, T.A.; Mileshkin, L.R.; Mackay, H.J.; Leary, A.; Powell, M.E.; Singh, N.; Crosbie, E.J.; Smit, V.T.H.B.M.; Creutzberg, C.L. & Bosse, T. (2020), HER2 status in high-risk endometrial cancers (PORTEC-3), Cancers 2021(1).
- Giardiello, D.; Hauptmann, M.; Steyerberg, E.W.; Adank, M.A.; Akdeniz, D.; Blom, J.C.; Blomqvist, C.; Bojesen, S.E.; Bolla, M.K.; Brinkhuis, M.; Chang-Claude, J.; Czene, K.; Devilee, P.; Dunning, A.M.; Easton, D.F.; Eccles, D.M.; Fasching, P.A.; Figueroa, J.; Flyger, H.; Garcia-Closas, M.; Haeberle, L.; Haiman, C.A.; Hall, P.; Hamann, U.; Hopper, J.L.; Jager, A.; Jakubowska, A.; Jung, A.; Keeman, R.; Koppert, L.B.; Kramer, I.; Lambrechts, D.; Marchand, L. le; Lindblom, A.; Lubinski, J.; Manoochehri, M.; Mariani, L.; Nevanlinna, H.; Oldenburg, H.S.A.; Pelders, S.; Pharoah, P.D.P.; Shah, M.; Siesling, S.; Smit, V.T.H.B.M.; Southey, M.C.; Tapper, W.J.; Tollenaar, R.A.E.M.; Broek, A.J. van den; Deurzen, C.H.M. van; Leeuwen, F.E. van; Ongeval, C. van; Van't Veer, L.J.; Wang, Q.; Wendt, C.; Westenend, P.J.; Hooning, M.J. & Schmidt, M.K. (2020), Prediction of contralateral breast cancer, Breast Cancer Research and Treatment 181(2): 423-434.
- Leon-Castillo, A.; Gilvazquez, E.; Nout, R.; Smit, V.T.H.B.M.; McAlpine, J.N.; McConechy, M.; Kommoss, S.; Brucker, S.Y.; Carlson, J.W.; Epstein, E.; Rau, T.T.; Soslow, R.A.; Ganesan, R.; Matias-Guiu, X.; Oliva, E.; Harrison, B.T.; Church, D.N.; Gilks, C.B. & Bosse, T. (2020), Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas, Journal of Pathology 250(3).
- Leon-Castillo, A.; Boer, S.M. de; Powell, M.E.; Mileshkin, L.R.; Mackay, H.J.; Leary, A.; Nijman, H.W.; Singh, N.; Pollock, P.M.; Bessette, P.; Fyles, A.; Haie-Meder, C.; Smit, V.T.H.B.M.; Edmondson, R.J.; Putter, H.; Kitchener, H.C.; Crosbie, E.J.; Bruyn, M. de; Nout, R.A.; Horeweg, N.; Creutzberg, C.L.; Bosse, T. & TransPORTEC Consortium (2020), Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer, Journal of Clinical Oncology 38(29): 3388-+.
- Creutzberg, C.L.; Leon-Castillo, A.; Boer, S.M. de; Powell, M.E.; Mileshkin, L.R.; Mackay, H.J.; Leary, A.; Nijman, H.W.; Singh, N.; Pollock, P.; Fyles, A.; Haie-Meder, C.; Smit, V.T.H.B.M.; Edmondson, R.J.; Putter, H.; Kitchener, H.C.; Crosbie, E.J.; Bruyn, M. de; Nout, R. & Bosse, T. (2019), Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy, Annals of Oncology 30: 899-+.
- Kortekaas, K.E.; Vijver, K.K. van de; Poelgeest, M.I.E. van; Gilks, C.B.; Smit, V.T.H.B.M.; Arif, S.; Arora, D.; Faruqi, A.; Ganesan, R.; Griffin, N.R.; Hale, R.; Hock, Y.E.; Horn, L.C.; McCluggage, W.G.; Mukonoweshuro, P.; Park, K.J.; Rous, B.; Tanchel, B.; Rompuy, A.S. van; Schalkwyk, G. van; Vella, J.; Vergine, M.; Singh, N. & Bosse, T. (2019), Practical guidance for measuring and reporting surgical margins in vulvar cancer, International Journal of Gynecological Pathology 39(5).
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; D'Amico, R.; Fyles, A.; Baron, M.H.; Jurgenliemk-Schulz, I.M.; Kitchener, H.C.; Nijman, H.W.; Wilson, G.; Brooks, S.; Gribaudo, S.; Provencher, D.; Hanzen, C.; Kruitwagen, R.F.; Smit, V.T.H.B.M.; Singh, N.; , V. do; Lissoni, A.; Nout, R.A.; Feeney, A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L. & PORTEC Study Grp (2019), Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial, The Lancet Oncology 20(9): 1273-1285.
- Peters, E.E.M.; Bartosch, C.; McCluggage, W.G.; Genestie, C.; Lax, S.F.; Nout, R.; Oosting, J.; Singh, N.; Smit, H.C.S.H.; Smit, V.T.H.B.M.; Vijver, K.K. van de & Bosse, T. (2019), Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer, Histopathology 75(1): 128-136.
- Jonge, M.M. de; Auguste, A.; Wijk, L.M. van; Schouten, P.C.; Meijers, M.; Haar, N.T. ter; Smit, V.T.H.B.M.; Nout, R.A.; Glaire, M.A.; Church, D.N.; Vrieling, H.; Job, B.; Boursin, Y.; Kroon, C.D. de; Rouleau, E.; Leary, A.; Vreeswijk, M.P.G. & Bosse, T. (2019), Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas, Clinical Cancer Research 25(3): 1087-1097.
- Giardiello, D.; Steyerberg, E.W.; Hauptmann, M.; Adank, M.A.; Akdeniz, D.; Blomqvist, C.; Bojesen, S.E.; Bolla, M.K.; Brinkhuis, M.; Chang-Claude, J.; Czene, K.; Devilee, P.; Dunning, A.M.; Easton, D.F.; Eccles, D.M.; Fasching, P.A.; Figueroa, J.; Flyger, H.; Garcia-Closas, M.; Haeberle, L.; Haiman, C.A.; Hall, P.; Hamann, U.; Hopper, J.L.; Jager, A.; Jakubowska, A.; Jung, A.; Keeman, R.; Kramer, I.; Lambrechts, D.; Marchand, L. le; Lindblom, A.; Lubinski, J.; Manoochehri, M.; Mariani, L.; Nevanlinna, H.; Oldenburg, H.S.A.; Pelders, S.; Pharoah, P.D.P.; Shah, M.; Siesling, S.; Smit, V.T.H.B.M.; Southey, M.C.; Tapper, W.J.; Tollenaar, R.A.E.M.; Broek, A.J. van den; Deurzen, C.H.M. van; Leeuwen, F.E. van; Ongeval, C. van; Van't Veer, L.J.; Wang, Q.; Wendt, C.; Westenend, P.J.; Hooning, M.J. & Schmidt, M.K. (2019), Prediction and clinical utility of a contralateral breast cancer risk model, Breast Cancer Research 21(1).
- Groot, S. de; Pijl, H.; Charehbili, A.; Ven, S. van de; Smit, V.T.H.B.M.; Meershoek-Klein Kranenbarg, E.; Heijns, J.B.; Warmerdam, L.J.C. van; Kessels, L.W.; Dercksen, M.W.; Pepels, M.J.A.E.; Laarhoven, H.W.M. van; Vriens, B.E.P.J.; Putter, H.; Fiocco, M.; Liefers, G.J.; Hoeven, J.J.M. van der; Nortier, J.W.R.; Kroep, J.R. & Dutch Breast Canc Res Grp (2019), Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01), Breast Cancer Research 21(1).
- Jonge, M.M. de; Ritterhouse, L.L.; Kroon, C.D. de; Vreeswijk, M.P.G.; Segal, J.P.; Puranik, R.; Rookus, M.A.; Hogervorst, F.B.L.; Leeuwen, F.E. van; Adank, M.A.; Schmidt, M.K.; Jenner, D.J.; Collee, J.M.; Ouweland, A.M.W. van den; Hooning, M.J.; Boere, I.A.; Asperen, C.J. van; Devilee, P.; Luijt, R.B. van der; Cronenburg, T.C.T.E.F. van; Wevers, M.R.; Mensenkamp, A.R.; Ausems, M.G.E.M.; Koudijs, M.J.; Meijers-Heijboer, H.E.J.; Os, T.A.M. van; Engelen, K. van; Gille, J.J.P.; Gomez-Garcia, E.B.; Blok, M.J.; Boer, M. de; Oosterwijk, J.C.; Hout, A.H. van der; Mourits, M.J.; Bock, G.H. de; Siesling, S.; Verloop, J.; Broek, E.C. van den; Hollema, H.; Smit, V.T.H.B.M.; Howitt, B.E.; Bosse, T. & HEBON Grp (2019), Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity, Clinical Cancer Research 25(24): 7517-7526.
- Majoor, B.C.J.; Boyce, A.M.; Bovee, J.V.M.G.; Smit, V.T.H.B.M.; Collins, M.T.; Cleton-Jansen, A.M.; Dekkers, O.M.; Hamdy, N.A.T.; Dijkstra, P.D.S. & Appelman-Dijkstra, N.M. (2018), Increased Risk of Breast Cancer at a Young Age in Women with Fibrous Dysplasia, Journal of Bone and Mineral Research 33(1): 84-90.
- Gool, I.C. van; Ubachs, J.E.H.; Stelloo, E.; Kroon, C.D. de; Goeman, J.J.; Smit, V.T.H.B.M.; Creutzberg, C.L. & Bosse, T. (2018), Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing, Histopathology 72(2): 248-258.
- Jonge, M.M. de; Ruano, D.; Eijk, R. van; Stoep, N. van der; Nielsen, M.; Wijnen, J.T.; Haar, N.T. ter; Baalbergen, A.; Bos, M.E.M.M.; Kagie, M.J.; Vreeswijk, M.P.G.; Gaarenstroom, K.N.; Kroep, J.R.; Smit, V.T.H.B.M.; Bosse, T.; Wezel, T. van & Asperen, C.J. van (2018), Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue, Journal of Molecular Diagnostics 20(5): 600-611.
- Boer, S.M. de; Wortman, B.G.; Bosse, T.; Powell, M.E.; Singh, N.; Hollema, H.; Wilson, G.; Chowdhury, M.N.; Mileshkin, L.; Pyman, J.; Katsaros, D.; Carinelli, S.; Fyles, A.; McLachlin, C.M.; Haie-Meder, C.; Duvillard, P.; Nout, R.A.; Verhoeven-Adema, K.W.; Putter, H.; Creutzberg, C.L.; Smit, V.T.H.B.M. & PORTEC Study Grp (2018), Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer, Annals of Oncology 29(2): 424-430.
- Temko, D.; Gool, I.C. van; Rayner, E.; Glaire, M.; Makino, S.; Brown, M.; Chegwidden, L.; Palles, C.; Depreeuw, J.; Beggs, A.; Stathopoulou, C.; Mason, J.; Baker, A.M.; Williams, M.; Cerundolo, V.; Rei, M.; Taylor, J.C.; Schuh, A.; Ahmed, A.; Amant, F.; Lambrechts, D.; Smit, V.T.H.B.M.; Bosse, T.; Graham, T.A.; Church, D.N. & Tomlinson, I. (2018), Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response, Journal of Pathology 245(3): 283-296.
- Wortman, B.G.; Creutzberg, C.L.; Putter, H.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Triest, B. van; Nijman, H.W.; Stelloo, E.; Bosse, T.; Boer, S.M. de; Putten, W.L.J. van; Smit, V.T.H.B.M.; Nout, R.A. & PORTEC Study Grp (2018), Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy, British Journal of Cancer 119(9): 1067-1074.
- Blok, E.J.; Engels, C.C.; Dekker-Ensink, G.; Kranenbarg, E.M.K.; Putter, H.; Smit, V.T.H.B.M.; Liefers, G.J.; Morden, J.P.; Bliss, J.M.; Coombes, R.C.; Bartlett, J.M.S.; Kroep, J.R.; Velde, C.J.H. van de & Kuppen, P.J.K. (2018), Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer, Breast Cancer Research and Treatment 171(1): 65-74.
- Gool, I.C. van; Rayner, E.; Osse, E.M.; Nout, R.A.; Creutzberg, C.L.; Tomlinson, I.P.M.; Church, D.N.; Smit, V.T.H.B.M.; Wind, N. de; Bosse, T. & Drost, M. (2018), Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues, Clinical Cancer Research 24(13): 3197-3203.
- Stephanie M. de Boer1* MD, Melanie E. Powell2 MD, Linda Mileshkin3 MD, Prof Dionyssios Katsaros4 MD, Prof Paul Bessette5 MD, Christine Haie-Meder6 MD, Petronella B. Ottevanger7 MD, Prof Jonathan A. Ledermann8 MD, Pearly Khaw9 MD, Alessandro Colombo10 MD, Prof Anthony Fyles11 MD, Marie-Helene Baron12 MD, Ina M. Jürgenliemk-Schulz13 MD, Prof Henry C. Kitchener14 MD, Prof Hans W. Nijman15 MD, Godfrey Wilson16 MD, Ilka Kolodziej17 MPH, Silvestro Carinelli18 MD, Ludy C.H.W. Lutgens19 MD, Prof Vincent T. Smit20 PhD, Naveena Singh21 MD, Remi A. Nout1 MD, Karen W. Verhoeven-Adema22 PhD, Prof Hein Putter23 PhD, Prof Carien L. Creutzberg1 MD & on behalf of the PORTEC study group#. (2018), Patterns of recurrence in the randomised PORTEC-3 trial of chemoradiotherapy for endometrial cancer.
- Wortman, B.G.; Bosse, T.; Nout, R.A.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Westerveld, H.; Berg, H. van den; Slot, A.; Winter, K.A.J. de; Verhoeven-Adema, K.W.; Smit, V.T.H.B.M.; Creutzberg, C.L. & PORTEC Study Grp (2018), Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial, Gynecologic Oncology 151(1): 69-75.
- Melief, S.M.; Visconti, V.V.; Visser, M.; Diepen, M. van; Kapiteijn, E.H.W.; Berg, J.H. van den; Haanen, J.B.A.G.; Smit, V.T.H.B.M.; Oosting, J.; Burg, S.H. van der & Verdegaal, E.M.E. (2017), Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature, Cancer Immunology Research 5(2): 170-179.
- Peters, I.T.A.; Steen, M.A. van der; Huisman, B.W.; Hilders, C.G.J.M.; Smit, V.T.H.B.M.; Vahrmeijer, A.L.; Sier, C.F.M.; Trimbos, J.B. & Kuppen, P.J.K. (2017), Morphological and phenotypical features of ovarian metastases in breast cancer patients, BMC Cancer 17.
- Peters, I.T.A.; Zwet, E.W. van; Smit, V.T.H.B.M.; Liefers, G.J.; Kuppen, P.J.K.; Hilders, C.G.J.M. & Trimbos, J.B. (2017), Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study, PLoS ONE 12(1).
- Roeke, T.; Sobral-Leite, M.; Dekker, T.J.A.; Wesseling, J.; Smit, V.T.H.B.M.; Tollenaar, R.A.E.M.; Schmidt, M.K. & Mesker, W.E. (2017), The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study, Breast Cancer Research and Treatment 166(2): 435-445.
- Haseth, S.B. de; Bakker, E.; Vermeer, M.H.; Idrissi, H. el; Bosse, T.; Smit, V.T.H.B.M.; Terron-Kwiatkowski, A.; McLean, W.H.I.; Peters, A.A.W. & Hes, F.J. (2017), A novel keratin 13 variant in a four-generation family with white sponge nevus, Clinical Case Reports 5(9): 1503-1509.
- Engelhardt, E.G.; Broek, A.J. van den; Linn, S.C.; Wishart, G.C.; Rutgers, E.J.T.; Velde, A.O. van de; Smit, V.T.H.B.M.; Voogd, A.C.; Siesling, S.; Brinkhuis, M.; Seynaeve, C.; Westenend, P.J.; Stiggelbout, A.M.; Tollenaar, R.A.E.M.; Leeuwen, F.E. van; Veer, L.J. van 't; Ravdin, P.M.; Pharaoh, P.D.P. & Schmidt, M.K. (2017), Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years, European Journal of Cancer 78: 37-44.
- Schmidt, M.K.; Broek, A.J. van den; Tollenaar, R.A.E.M.; Smit, V.T.H.B.M.; Westenend, P.J.; Brinkhuis, M.; Oosterhuis, W.J.W.; Wesseling, J.; Janssen-Heijnen, M.L.; Jobsen, J.J.; Jager, A.; Voogd, A.C.; Leeuwen, F.E. van & Veer, L.J. van 't (2017), Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women, Journal of the National Cancer Institute 109(8).
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.R.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; Colombo, A.; Fyles, A.W.; Baron, M.H.; Kitchener, H.C.; Nijman, H.; Kruitwagen, R.F.P.M.; Jurgenliemk-Schulz, I.M.; Nout, R.A.; Smit, V.T.H.B.M.; Putter, H. & Creutzberg, C.L. (2017), Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.
- Broek, A.J. van den; Veer, L.J. van 't; Hooning, M.J.; Cornelissen, S.; Broeks, A.; Rutgers, E.J.; Smit, V.T.H.B.M.; Cornelisse, C.J.; Beek, M. van; Janssen-Heijnen, M.L.; Seynaeve, C.; Westenend, P.J.; Jobsen, J.J.; Siesling, S.; Tollenaar, R.A.E.M.; Leeuwen, F.E. van & Schmidt, M.K. (2016), Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers, Journal of Clinical Oncology 34(5): 409-+.
- Peters, I.T.A.; Hilders, C.G.J.M.; Sier, C.F.M.; Vahrmeijer, A.L.; Smit, V.T.H.B.M.; Trimbos, J.B. & Kuppen, P.J.K. (2016), Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue, Archives of Gynecology and Obstetrics 294(2): 385-393.
- Gent, M.D.J.M. van; Nicolae-Cristea, A.R.; Kroon, C.D. de; Osse, E.M.; Kagie, M.J.; Trimbos, J.B.M.Z.; Hazelbag, H.M.; Smit, V.T.H.B.M. & Bosse, T. (2016), Exploring Morphologic and Molecular Aspects of Endometrial Cancer Under Progesterone Treatment in the Context of Fertility Preservation, International Journal of Gynecological Cancer 26(3): 483-490.
- Charehbili, A.; Hamdy, N.A.T.; Smit, V.T.H.B.M.; Kessels, L.; Bochove, A. van; Laarhoven, H.W. van; Putter, H.; Kranenbarg, E.M.K.; Leeuwen-Stok, A.E. van; Hoeven, J.J.M. van der; Velde, C.J.H. van de; Nortier, J.W.R.; Kroep, J.R. & Dutch Breast Canc Res Grp BOOG (2016), Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01), Breast 25: 69-74.
- Nooij, L.S.; Slot, M.A. van der; Dekkers, O.M.; Stijnen, T.; Gaarenstroom, K.N.; Creutzberg, C.L.; Smit, V.T.H.B.M.; Bosse, T. & Poelgeest, M.I.E. van (2016), Tumour-free margins in vulvar squamous cell carcinoma: Does distance really matter?, European Journal of Cancer 65: 139-149.
- Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B.; Ledermann, J.A.; Khaw, P.; Colombo, A.; Fyles, A.; Baron, M.H.; Kitchener, H.C.; Nijman, H.W.; Kruitwagen, R.F.; Nout, R.A.; Verhoeven-Adema, K.W.; Smit, V.T.; Putter, H.; Creutzberg, C.L. & PORTEC Study Grp (2016), Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial, Lancet Oncology 17(8): 1114-1126.
- Engels, C.C.; Glas, N.A. de; Sajet, A.; Bastiaannet, E.; Smit, V.T.H.B.M.; Kuppen, P.J.K.; Seynaeve, C.; Velde, C.J.H. van de & Liefers, G.J. (2016), The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis, Molecular Oncology 10(4): 509-516.
- Engels, C.C.; Kiderlen, M.; Bastiaannet, E.; Eijk, R. van; Mooyaart, A.; Smit, V.T.H.B.M.; Craen, A.J.M. de; Kuppen, P.J.K.; Kroep, J.R.; Velde, C.J.H. van de & Liefers, G.J. (2016), The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis, Breast Cancer Research and Treatment 156(2): 361-370.
- Engels, C.C.; Kiderlen, M.; Bastiaannet, E.; Mooyaart, A.L.; Vlierberghe, R. van; Smit, V.T.H.B.M.; Kuppen, P.J.K.; Velde, C.J.H. van de & Liefers, G.J. (2016), The clinical prognostic value of molecular intrinsic tumor subtypes in older breast cancer patients: A FOCUS study analysis, Molecular Oncology 10(4): 594-600.
- Nooij, L.S.; Dreef, E.J.; Smit, V.T.H.B.M.; Poelgeest, M.I.E. van & Bosse, T. (2016), Stathmin is a highly sensitive and specific biomarker for vulvar high-grade squamous intraepithelial lesions, Journal of Clinical Pathology 69(12): 1070-1075.
- Hoogstins, C.E.S.; Tummers, Q.R.J.G.; Gaarenstroom, K.N.; Kroon, C.D. de; Trimbos, J.B.M.Z.; Bosse, T.; Smit, V.T.H.B.M.; Vuyk, J.; Velde, C.J.H. van de; Cohen, A.F.; Low, P.S.; Burggraaf, J. & Vahrmeijer, A.L. (2016), A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer, Clinical Cancer Research 22(12): 2929-2938.
- Stelloo, E.; Versluis, M.A.; Nijman, H.W.; Bruyn, M. de; Plat, A.; Osse, E.M.; Dijk, R.H. van; Nout, R.A.; Creutzberg, C.L.; Bock, G.H. de; Smit, V.T.; Bosse, T. & Hollema, H. (2016), Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer, Oncotarget 7(26): 39885-39893.
- Stelloo, E.; Nout, R.A.; Osse, E.M.; Jurgenliemk-Schulz, I.J.; Jobsen, J.J.; Lutgens, L.C.; Steen-Banasik, E.M. van der; Nijman, H.W.; Putter, H.; Bosse, T.; Creutzberg, C.L. & Smit, V.T.H.B.M. (2016), Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts, Clinical Cancer Research 22(16): 4215-4224.
- Gool, I.C. van; Stelloo, E.; Nout, R.A.; Nijman, H.W.; Edmondson, R.J.; Church, D.N.; MacKay, H.J.; Leary, A.; Powell, M.E.; Mileshkin, L.; Creutzberg, C.L.; Smit, V.T.H.B.M. & Bosse, T. (2016), Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer, Modern Pathology 29(2): 174-181.
- Engels, C.C.; Charehbili, A.; Velde, C.J.H. van de; Bastiaannet, E.; Sajet, A.; Putter, H.; Vliet, E.A. van; Vlierberghe, R.L.P. van; Smit, V.T.H.B.M.; Bartlett, J.M.S.; Seynaeve, C.; Liefers, G.J. & Kuppen, P.J.K. (2015), The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis, Breast Cancer Research and Treatment 149(3): 587-596.
- Groot, S. de; Charehbili, A.; Janssen, L.G.M.; Dijkgraaf, E.M.; Smit, V.T.H.B.M.; Kessels, L.W.; Bochove, A. van; Laarhoven, H.W.M. van; Kranenbarg, E.M.K.; Leeuwen-Stok, A.E. van; Liefers, G.J.; Velde, C.J.H. van de; Nortier, J.W.R.; Hoeven, J.J.M. van der; Pijl, H. & Kroep, J.R. (2015), Thyroid function is associated with the response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial on behalf of the Dutch Breast Cancer Research Group (BOOG 2010-01), Cancer Research 75(9).
- Hoekman, E.J.; Smit, V.T.H.B.M.; Fleming, T.P.; Louwe, L.A.; Fleuren, G.J. & Hilders, C.G.J.M. (2015), Searching for metastases in ovarian tissue before autotransplantation: a tailor-made approach, Fertility and Sterility 103(2): 469-477.
- Gaarenstroom, K.N.; Kroon, C.D. de; Hoogstins, C.E.S.; Tummers, Q.R.J.G.; Beltman, J.J.; Poelgeest, M.I.E. van; Trimbos, J.B.M.Z.; Bosse, T.; Burggraaf, J.; Smit, V.T.H.B.; Vuyk, J.; Cohen, A.F.; Velde, C.J.H. van de; Low, P.S. & Vahrmeijer, A.L. (2015), INTRA-OPERATIVE VAPORIZATION OF OVARIAN CANCER METASTASES UNDER FLUORESCENT GUIDANCE: A CASE REPORT, International Journal of Gynecological Cancer 25(9): 1346-1347.
- Bosse, T.; Peters, E.E.M.; Creutzberg, C.L.; Jurenliemk-Schulz, I.M.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Smit, V.T.H.B.M. & Nout, R.A. (2015), Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer - A pooled analysis of PORTEC 1 and 2 trials, European Journal of Cancer 51(13): 1742-1750.
- Mesker, W.E.; Dekker, T.J.A.; Kruijf, E.M. de; Engels, C.C.; Pelt, G.W. van; Smit, V.T.H.B.M. & Tollenaar, R.A.E.M. (2015), Comment on: The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer, British Journal of Cancer 112(11): 1832-1833.
- Dekker, T.J.A.; Charehbili, A.; Smit, V.T.H.B.M.; Dijke, P. ten; Kranenbarg, E.M.K.; Velde, C.J.H. van de; Nortier, J.W.R.; Tollenaar, R.A.E.M.; Mesker, W.E. & Kroep, J.R. (2015), Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial, Molecular Oncology 9(6): 1120-1128.
- Gool, I. van; Eggink, F.; Freeman-Mills, L.; Stelloo, E.; Marchi, E.; Palles, C.; Bruyn, M. de; Nout, R.; Kroon, C. de; Osse, M.; Klenerman, P.; Creutzberg, C.; Tomlinson, I.; Smit, V.; Nijman, H.; Bosse, T. & Church, D. (2015), POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer, European Journal of Cancer 51: S29-S29.
- Versluis, M.A.; Jong, R.A. de; Plat, A.; Bosse, T.; Smit, V.T.; Mackay, H.; Powell, M.; Leary, A.; Mileshkin, L.; Kitchener, H.C.; Crosbie, E.J.; Edmondson, R.J.; Creutzberg, C.L.; Hollema, H.; Daemen, T.; Bock, G.H. de & Nijman, H.W. (2015), Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters, British Journal of Cancer 113(5): 786-793.
- Dekker, T.J.A.; Borg, S. ter; Hooijer, G.K.J.; Meijer, S.L.; Wesseling, J.; Boers, J.E.; Schuuring, E.; Bart, J.; Gorp, J. van; Bult, P.; Riemersma, S.A.; Deurzen, C.H.M. van; Sleddens, H.F.B.M.; Mesker, W.E.; Kroep, J.R.; Smit, V.T.H.B.M. & Vijver, M.J. van de (2015), Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach (vol 152, pg 247, 2015), Breast Cancer Research and Treatment 152(2): 253-253.
- Onstenk, W.; Kraan, J.; Mostert, B.; Timmermans, M.M.; Charehbili, A.; Smit, V.T.H.B.M.; Kroep, J.R.; Nortier, J.W.R.; Ven, S.V. de; Heijns, J.B.; Kessels, L.; Laarhoven, H.M. van; Bos, M.M.E.M.; Velde, C.J.H. van de; Gratama, J.W.; Sieuwerts, A.M.; Martens, J.W.M.; Foekens, J.A. & Sleijfer, S. (2015), Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy, Molecular Cancer Therapeutics 14(3): 821-827.
- Dijkgraaf, E.M.; Santegoets, S.J.A.M.; Reyners, A.K.L.; Goedemans, R.; Nijman, H.W.; Poelgeest, M.I.E. van; Erkel, A.R. van; Smit, V.T.H.B.M.; Daemen, T.A.H.H.; Hoeven, J.J.M. van der; Melief, C.J.M.; Welters, M.J.P.; Kroep, J.R. & Burg, S.H. van der (2015), A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer, Oncotarget 6(31): 32228-32243.
- Nijenhuis, M.V.; Groen, E.; Dekker, T.J.; Drukker, C.A.; Sanders, J.; Smit, V.T.; Linn, S.; Rutgers, E.J. & Wesseling, J. (2015), Tumor heterogeneity impairs robustness of Ki67 scoring in breast cancer, Cancer Research 75(9).
- Creutzberg, C.L.; Boer, S.M. de; Putter, H.; Powell, M.; Mileshkin, L.R.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ledermann, J.A.; Ottevanger, P.B.; Khaw, P.; Colombo, A.; Fyles, A.W.; Baron, M.H.; Nijman, H.W.; Nout, R.A.; Smit, V.T.H.B.M.; Verhoeven-Adema, K.; Kruitwagen, R.F.P.M. & Kitchener, H.C. (2015), Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial.
- Bosse, T.; Peters, E.E.M.; Creutzberg, C.L.; Jurenliemk-Schulz, I.M.; Jobsen, J.J.; Mens, J.W.M.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Smit, V.T.H.B.M. & Nout, R.A. (2015), Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer, European Journal of Cancer 51(13).
- Charehbili, A.; Ven, S. van de; Smit, V.T.H.B.M.; Kranenbarg, E.K.; Hamdy, N.A.T.; Putter, H.; Heijns, J.B.; Warmerdam, L.J.C. van; Kessels, L.; Dercksen, M.; Pepels, M.J.; Maartense, E.; Laarhoven, H.W.M. van; Vriens, B.; Wasser, M.N.; Leeuwen-Stok, A.E. van; Liefers, G.J.; Velde, C.J.H. van de; Nortier, J.W.R.; Kroep, J.R. & Dutch Breast Canc Res Grp BOOG (2014), Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01), Annals of Oncology 25(5): 998-1004.
- Bosse, T.; Nout, R.A.; Stelloo, E.; Dreef, E.; Nijman, H.W.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Creutzberg, C.L. & Smit, V.T.H.B.M. (2014), L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results, European Journal of Cancer 50(15): 2602-2610.
- Aapro, M.S.; Laurentiis, M. de; Mamounas, E.; Martin, M.; Rea, D.; Rouzier, R.; Smit, V. & Thomssen, C. (2014), ADOPTION OF MULTI-GENE ASSAYS IN HR +, HER2-BREAST CANCER (BC) PATIENTS IN EUROPE: RESULTS OF THE MULTIDISCIPLINARY APPLICATION OF GENOMICS IN CLINICAL PRACTICE (MAGIC) SURVEY, Annals of Oncology 25.
- Vogelaar, F.J.; Reimers, M.S.; Linden, R.L.A. van der; Linden, J.C. van der; Smit, V.T.H.B.M.; Lips, D.J.; Velde, C.J.H. van de & Bosscha, K. (2014), The Diagnostic Value of One-Step Nucleic acid Amplification (OSNA) for Sentinel Lymph Nodes in Colon Cancer Patients, Annals of Surgical Oncology 21(12): 3924-3930.
- Nout, R.A.; Peters, E.E.M.; Jurgenlienik-Schulz, I.M.; Jobsen, J.J.; Mens, J.W.M.; Stelloo, E.; Smit, V.T.H.; Bosse, T. & Creutzberg, C.L. (2014), Quantification of LVSI Improves Its Strength as Prognostic Factor for Recurrence in Stage I Endometrial Cancer Patients Treated in the PORTEC Trials, International Journal of Radiation Oncology - Biology - Physics 90: S110-S111.
- Church, D.; Stelloo, E.; Nout, R.A.; Valtcheva, N.; Depreeuw, J.; Haar, N. ter; Amant, F.; Tomlinson, I.P.M.; Wild, P.; Smit, V.; Creutzberg, C.L. & Bosse, T. (2014), PROGNOSTIC SIGNIFICANCE OF POLE EXONUCLEASE DOMAIN MUTATION IN EARLY STAGE ENDOMETRIAL CANCER, International Journal of Gynecological Cancer 24(9): 1601-1602.
- Dekker, T.J.A.; Balluff, B.D.; Jones, E.A.; Schone, C.D.; Schmitt, M.; Aubele, M.; Kroep, J.R.; Smit, V.T.H.B.M.; Tollenaar, R.A.E.M.; Mesker, W.E.; Walch, A. & McDonnell, L.A. (2014), Multicenter Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) Identifies Proteomic Differences in Breast-Cancer-Associated Stroma, Journal of Proteome Research 13(11): 4730-4738.
- Bosse, T.; Nout, R.A.; Stelloo, E.; Mackay, H.J.; Church, D.; Powell, M.; Leary, A.; Mileshkin, L.; Kitchener, H.; Smit, V. & Creutzberg, C.L. (2014), MOLECULAR PROFILING OF HIGH-RISK ENDOMETRIAL CANCER; A TRANSPORTEC PILOT STUDY, International Journal of Gynecological Cancer 24(9): 1503-1504.
- Derr, R.S.; Hoesel, A.Q. van; Benard, A.; Goossens-Beumer, I.J.; Sajet, A.; Dekker-Ensink, N.G.; Kruijf, E.M. de; Bastiaannet, E.; Smit, V.T.H.B.M.; Velde, C.J.H. van de & Kuppen, P.J.K. (2014), High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients, BMC Cancer 14.
- Kruijf, E.M. de; Bastiaannet, E.; Ruberta, F.; Craen, A.J.M. de; Kuppen, P.J.K.; Smit, V.T.H.B.M.; Velde, C.J.H. van de & Liefers, G.J. (2014), Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients, Molecular Oncology 8(5): 1014-1025.
- Charehbili, A.; Wasser, M.N.; Smit, V.T.H.B.M.; Putter, H.; Leeuwen-Stok, A.E. van; Kranenbarg, W.M.M.K.; Liefers, G.J.; Velde, C.J.H. van de; Nortier, J.W.R. & Kroep, J.R. (2014), Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer, EJSO - European Journal of Surgical Oncology 40(10): 1216-1221.
- Spaans, V.M.; Trietsch, M.D.; Crobach, S.; Stelloo, E.; Kremer, D.; Osse, E.M.; Haar, N.T. ter; Eijk, R. van; Muller, S.; Wezel, T. van; Trimbos, J.B.; Bosse, T.; Smit, V.T.H.B.M. & Fleuren, G.J. (2014), Designing a High-Throughput Somatic Mutation Profiling Panel Specifically for Gynaecological Cancers, PLoS ONE 9(3).
- Stelloo, E.; Nout, R.A.; Naves, L.C.L.M.; Haar, N.T. ter; Creutzberg, C.L.; Smit, V.T.H.B.M. & Bosse, T. (2014), High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma, Gynecologic Oncology 133(2): 197-204.
- Peters, I.T.A.; Kuppen, P.J.K.; Sier, K.E.M.; Dekker-Ensink, N.G.; Vlierberghe, R.L.P. van; Smit, V.T.H.B.M.; Trimbos, J.B.M.Z. & Hilders, C.G.J.M. (2014), THE ASSESSMENT OF BREAST TUMOR MARKERS IN AN OVARY ENVIRONMENT: A COMPREHENSIVE IMMUNOHISTOCHEMICAL ANALYSIS., Fertility and Sterility 102(3): E156-E157.
- Aapro, M.; Laurentiis, M. de; Mamounas, E.; Martin, M.; Rea, D.; Rouzier, R.; Smit, V. & Thomssen, C. (2014), Patient attributes considered for decision-making with regard to adjuvant chemotherapy in early stage HR+, HER2-breast cancer patients: Results of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey, European Journal of Cancer 50: S44-S45.
- Vorst, J.R. van der; Schaafsma, B.E.; Hutteman, M.; Verbeek, F.P.R.; Liefers, G.J.; Hartgrink, H.H.; Smit, V.T.H.B.M.; Lowik, C.W.G.M.; Velde, C.J.H. van de; Frangioni, J.V. & Vahrmeijer, A.L. (2013), Near-infrared fluorescence-guided resection of colorectal liver metastases, Cancer 119(18): 3411-3418.
- Onstenk, W.; Kraan, J.; Charehbili, A.; Mostert, B.; Smit, V.T.H.B.M.; Kroep, J.R.; Nortier, J.W.R.; Liefers, G.J.; Ven, S. van de; Heijns, J.B.; Kessels, L.; Laarhoven, H.W.M. van; Bos, M.M.E.M.; Velde, C.J.H. van de; Gratama, J.W.; Sieuwerts, A.M.; Martens, J.W.M.; Foekens, J.A. & Sleijfer, S. (2013), A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOG) side study., Journal of Clinical Oncology 31(15).
- Bosse, T.; Haar, N.T. ter; Seeber, L.M.; Diest, P.J. van; Hes, F.J.; Vasen, H.F.A.; Nout, R.A.; Creutzberg, C.L.; Morreau, H. & Smit, V.T.H.B.M. (2013), Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer, Modern Pathology 26(11): 1525-1535.
- Dekker, T.J.A.; Smit, V.T.H.B.M.; Hooijer, G.K.J.; Vijver, M.J. van de; Mesker, W.E.; Tollenaar, R.A.E.M.; Nortier, J.W.R. & Kroep, J.R. (2013), Reliability of core needle biopsy for determining ER and HER2 status in breast cancer, Annals of Oncology 24(4): 931-937.
- Kruijf, E.M. de; Engels, C.C.; Water, W. van de; Bastiaannet, E.; Smit, V.T.H.B.M.; Velde, C.J.H. van de; Liefers, G.J. & Kuppen, P.J.K. (2013), Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients, Breast Cancer Research and Treatment 142(2): 355-364.
- Engels, C.C.; Ruberta, F.; Kruijf, E.M. de; Pelt, G.W. van; Smit, V.T.H.B.M.; Liefers, G.J.; Matsushima, T.; Shibayama, M.; Ishihara, H.; Velde, C.J.H. van de & Kuppen, P.J.K. (2013), The prognostic value of apoptotic and proliferative markers in breast cancer, Breast Cancer Research and Treatment 142(2): 323-339.
- Nout, R.; Boer, S. de; Putter, H.; Jurgenliemk-Schulz, I.; Jobsen, J.; Lutgens, L.; Steen-Banasik, E. van der; Mens, J.W.; Slot, A.; Stenfert-Kroese, M.; Verhoeven-Adema, K.; Stelloo, E.; Bosse, T.; Smit, V. & Creutzberg, C. (2013), Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Long term results of the randomized PORTEC-2 trial, European Journal of Cancer 49: S714-S714.
- Dekker, T.J.A.; Charehbili, A.; Smit, V.T.; Kranenbarg, E.M.M.K.; Tollenaar, R.A.E.M.; Velde, C.J.H. van de; Liefers, G.J.; Nortier, J.W.R.; Mesker, W.E. & Kroep, J.R. (2013), Tumor stroma ratio as a predictor for response to neoadjuvant chemotherapy (TAC) in breast cancer (BC): A Dutch Breast Cancer Trialists' Group (BOOG) side-study, European Journal of Cancer 49: S204-S204.
- Vogelaar, J.; Reimers, M.S.; Linden, R.L.A. van der; Linden, J.C. van der; Smit, V.; Takata, H.; Lips, D.J.; Velde, C.J.H. van de & Bosscha, K. (2013), The diagnostic value of one step nucleic acid amplification (OSNA) for sentinel lymph nodes in colon cancer, European Journal of Cancer 49: S200-S201.
- Gent, M.D.J.M. van; Nicolae-Cristea, A.R.; Kroon, C.D. de; Kagie, M.J.; Trimbos, J.M.B.Z.; Hazelbag, H.M.; Osse, E.M.; Bosse, T. & Smit, V. (2013), PROGESTERONE RESPONSIVENESS IN PREMENOPAUSAL PATIENTS WITH GRADE 1 ENDOMETRIOID ENDOMETRIAL CANCER IS INDEPENDENT OF MOLECULAR ALTERATIONS IN WNT- AND PI3K-AKT-PATHWAYS, International Journal of Gynecological Cancer 23(8).
- Spaans, V.M.; Trietsch, M.D.; Peters, A.A.W.; Smit, V.; Jordanova, E.S. & Fleuren, G.J. (2013), PRECISE DISCRIMINATION OF CERVICAL CARCINOMA SUBTYPES IN COMBINATION WITH SOMATIC MUTATION PROFILING CONTRIBUTES TO PREDICTING DISEASE OUTCOME, International Journal of Gynecological Cancer 23(8).
- Oosterhuis, J.W.; Peeters, S.H.P.; Smit, V.T.H.B.M.; Stoop, H.; Looijenga, L.H.J.; Elzevier, H.W. & Osanto, S. (2013), Patient with two secondary somatic-type malignancies in a late recurrence of a testicular non-seminoma: illustration of potential and flaw of the cancer stem cell therapy concept, International Journal of Developmental Biology 57(2-4): 153-157.
- Creutzberg, C.L.; Stiphout, R.G.P.M. van; Nout, R.A.; Lutgens, L.C.H.W.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Smit, V.T.H. & Lambin, P. (2013), Nomogram for prediction of outcome for patients with endometrium cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials, European Journal of Cancer 49: S726-S727.
- Trietsch, M.; Spaans, V.M.; Crobach, S.; Kremer, D.; Osse, E.M.; Haar, N.T. ter; Eijk, R. van; Muller, S.; Bartholemy, D.; Wezel, T. van; Trimbos, J.B.M.Z.; Bosse, T.; Smit, V. & Fleuren, G.J. (2013), INHIBITION OF DNA-PK RECOVERS HR FUNCTION AND RESULTS IN PLATINUM RESISTANCE IN AN OVARIAN CANCER CELL LINE MODEL, International Journal of Gynecological Cancer 23(8).
- Dekker, T.J.A.; Velde, C.J.H. van de; Pelt, G.W. van; Kroep, J.R.; Julien, J.P.; Smit, V.T.H.B.M.; Tollenaar, R.A.E.M. & Mesker, W.E. (2013), Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854), Breast Cancer Research and Treatment 139(2): 371-379.
- Hughes, L.A.E.; Melotte, V.; Schrijver, J. de; Maat, M. de; Smit, V.T.H.B.M.; Bovee, J.V.M.G.; French, P.J.; Brandt, P.A. van den; Schouten, L.J.; Meyer, T. de; Criekinge, W. van; Ahuja, N.; Herman, J.G.; Weijenberg, M.P. & Engeland, M. van (2013), The CpG Island Methylator Phenotype: What's in a Name?, Cancer Research 73(19): 5858-5868.
- Charehbili, A.; Ven, S. van de; Liefers, G.J.; Smit, V.T.H.B.M.; Putter, H.; Heijns, J.B.; Warmerdam, L. van; Kessels, L.; Dercksen, W.; Pepels, M.J.; Maartense, E.; Laarhoven, H.W.M. van; Vriens, B.; Wasser, M.N.; Hamdy, N.A.T.; Kranenbarg, E.M.K.; Leeuwen-Stok, E. van; Velde, C.J.H. van de; Kroep, J.R. & Nortier, J.W.R. (2013), NEOZOTAC: Efficacy results from a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC)-A Dutch Breast Cancer Trialists' Group (BOOG) study, Journal of Clinical Oncology 31(15).
- Dekker, T.J.A.; Velde, C.J.H. van de; Bruggen, D. van; Mesker, W.E.; Hoeven, J.J.M. van der; Kroep, J.R.; Tollenaar, R.A.E.M. & Smit, V.T.H.B.M. (2013), Quantitative assessment of lymph vascular space invasion (LVSI) provides important prognostic information in node-negative breast cancer, Annals of Oncology 24(12): 2994-2998.
- Stelloo, E.; Nout, R.A.; Naves, L.C.L.M.; Haar, N.T. ter; Creutzberg, C.L.; Smit, T.H.B.M. & Bosse, T. (2013), HIGH CORRELATION OF MOLECULAR TUMOR ALTERATIONS IN ENDOMETRIAL CURRETAGE AND HYSTERECTOMY-SPECIMENS IN PATIENTS WITH ENDOMETRIAL CARCINOMA, International Journal of Gynecological Cancer 23(8).
- Steenwijk, P.J.D. van; Ramwadhdoebe, T.H.; Goedemans, R.; Doorduijn, E.M.; Ham, J.J. van; Gorter, A.; Hall, T. van; Kuijjer, M.L.; Poelgeest, M.I.E. van; Burg, S.H. van der & Jordanova, E.S. (2013), Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma.
- Trietsch, M.D.; Peters, A.A.W.; Gaarenstroom, K.N.; Koningsbrugge, S.H.L. van; Haar, N.T. ter; Osse, E.M.; Halbesma, N. & Fleuren, G.J. (2013), Spindle cell morphology is related to poor prognosis in vulvar squamous cell carcinoma, British Journal of Cancer 109(8): 2259-2265.
- Poelgeest, M.I.E. van; Welters, M.J.P.; Esch, E.M.G. van; Stynenbosch, L.F.M.; Kerpershoek, G.; Meerten, E.L.V. van; Hende, M. van den; Lowik, M.J.G.; Berends-van der Meer, D.M.A.; Fathers, L.M.; Valentijn, A.R.P.M.; Oostendorp, J.; Fleuren, G.J.; Melief, C.J.M.; Kenter, G.G. & Burg, S.H. van der (2013), HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial, Journal of Translational Medicine 11.
- Tillaart, S.A.H.M. van den; Corver, W.E.; Neto, D.R.; Haar, N.T. ter; Goeman, J.J.; Trimbos, J.B.M.Z.; Fleuren, G.J. & Oosting, J. (2013), Loss of Heterozygosity and Copy Number Alterations in Flow-Sorted Bulky Cervical Cancer, PLoS ONE 8(7).
- Charehbili, A.; Ven, S. van de; Liefers, G.J.; Smit, V.T.; Wasser, M.N.; Kranenbarg, E.M.M.K.; Leeuwen-Stok, A.E. van; Velde, C.J.H. van de; Nortier, J.W.R. & Kroep, J.R. (2013), Clinical and pathological response after neoadjuvant chemotherapy with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer, European Journal of Cancer 49: S401-S401.
- Charehbili, A.; Fontein, D.B.Y.; Smit, V.T.; Wasser, M.N.; Leeuwen-Stok, A.E. van; Kranenbarg, E.M.M.K.; Velde, C.J.H. van de; Liefers, G.J.; Nortier, J.W.R. & Kroep, J.R. (2013), Accuracy of treatment response assessment modalities after neoadjuvant therapy: A Dutch Breast Cancer Trialists' Group (BOOG) substudy, European Journal of Cancer 49: S468-S468.
- Huijbers, A.; Tollenaar, R.A.E.M.; Pelt, G.W. van; Zeestraten, E.C.M.; Dutton, S.; McConkey, C.C.; Domingo, E.; Smit, V.T.H.B.M.; Midgley, R.; Warren, B.F.; Johnstone, E.C.; Kerr, D.J. & Mesker, W.E. (2013), The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.
- Kruijf, E.M. de; Dekker, T.J.A.; Hawinkels, L.J.A.C.; Putter, H.; Smit, V.T.H.B.M.; Kroep, J.R.; Kuppen, P.J.K.; Velde, C.J.H. van de; Dijke, P. ten; Tollenaar, R.A.E.M. & Mesker, W.E. (2013), The prognostic role of TGF-beta signaling pathway in breast cancer patients, Annals of Oncology 24(2): 384-390.
- Saadatmand, S.; Kruijf, E.M. de; Sajet, A.; Dekker-Ensink, N.G.; Nes, J.G.H. van; Putter, H.; Smit, V.T.H.B.M.; Velde, C.J.H. van de; Liefers, G.J. & Kuppen, P.J.K. (2013), Expression of cell adhesion molecules and prognosis in breast cancer.
- Kruijf, E. de; Engels, C.; Water, W. van de; Bastiaannet, E.; Smit, V.; Velde, C. van de; Liefers, G.J. & Kuppen, P. (2012), Tumor Immune Subtypes Distinguish Tumor Subclasses With Clinical Implications in Breast Cancer Patients, Journal of Immunotherapy 35(9): 756-756.
- Kruijf, E. de; Bastiaannet, E.; Ruberta, F.; Sorlie, T.; Craen, A.J.M. de; Kuppen, P.J.K.; Smit, V.; Velde, C.J.H. van de & Liefers, G.J. (2012), Comparison of Frequencies and Prognostic Effect of Molecular Subtypes Between Young and Elderly Breast Cancer Patients, European Journal of Cancer 48: S129-S130.
- Dekker, T.J.A.; Borg, S. ter; Hooijer, G.K.J.; Meijer, S.L.; Wesseling, J.; Boers, J.E.; Schuuring, E.; Bart, J.; Gorp, J. van; Mesker, W.E.; Kroep, J.R.; Smit, V.T.H.B.M. & Vijver, M.J. van de (2012), Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach, Breast Cancer Research 14(3): -.
- Heusinkveld, M.; Goedemans, R.; Briet, R.J.P.; Gelderblom, H.; Nortier, J.W.R.; Gorter, A.; Smit, V.T.H.B.M.; Langeveld, A.P.M.; Jansen, J.C. & Burg, S.H. van der (2012), Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer., International Journal of Cancer.
- van der Vorst JR, Vahrmeijer AL, Hutteman M, Bosse T, Smit VT, van de Velde CJ, Frangioni JV & Bonsing BA (2012), Near-infrared fluorescence imaging of a solitary fibrous tumor of the pancreas using methylene blue., World Journal of Gastrointestinal Surgery 4(7): 180-4.
- Nout, R.A.; Bosse, T.; Creutzberg, C.L.; Jurgenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Eijk, R. van; Haar, N.T. ter & Smit, V.T.H.B.M. (2012), Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/beta-catenin and P53 pathway activation, Gynecologic Oncology 126(3): 466-473.
- Kruijf, E.M. de; Sajet, A.; Nes, J.G.H. van; Putter, H.; Smit, V.T.H.B.M.; Eagle, R.A.; Jafferji, I.; Trowsdale, J.; Liefers, G.J.; Velde, C.J.H. van de & Kuppen, P.J.K. (2012), NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study, BMC Cancer 12: -.
- Mieog, J.S.D.; Kruijf, E.M. de; Bastiaannet, E.; Kuppen, P.J.K.; Sajet, A.; Craen, A.J.M. de; Smit, V.T.H.B.M.; Velde, C.J.H. van de & Liefers, G.J. (2012), Age determines the prognostic role of the cancer stem cell marker aldehyde dehydrogenase-1 in breast cancer., BMC Cancer 12: 42.
- Mieog, J.S.D.; Hutteman, M.; Vorst, J.R. van der; Kuppen, P.J.K.; Que, I.; Dijkstra, J.; Kaijzel, E.L.; Prins, F.; Lowik, C.W.G.M.; Smit, V.T.H.B.M.; Velde, C.J.H. van de & Vahrmeijer, A.L. (2011), Image-guided tumor resection using real-time near-infrared fluorescence in a syngeneic rat model of primary breast cancer, Breast Cancer Research and Treatment 128(3): 679-689.
- Mieog, J.S.D.; Troyan, S.L.; Hutteman, M.; Donohoe, K.J.; Vorst, J.R. van der; Stockdale, A.; Liefers, G.J.; Choi, H.S.; Gibbs-Strauss, S.L.; Putter, H.; Gioux, S.; Kuppen, P.J.K.; Ashitate, Y.; Lowik, C.W.G.M.; Smit, V.T.H.B.M.; Oketokoun, R.; Ngo, L.H.; Velde, C.J.H. van de; Frangioni, J.V. & Vahrmeijer, A.L. (2011), Toward Optimization of Imaging System and Lymphatic Tracer for Near-Infrared Fluorescent Sentinel Lymph Node Mapping in Breast Cancer, Annals of Surgical Oncology 18(9): 2483-2491.
- Lips, D.J.; Koebrugge, B.; Liefers, G.J.; Linden, J.C. van de; Smit, V.T.H.B.M.; Pruijt, H.F.M.; Putter, H.; Velde, C.J.H. van de & Bosscha, K. (2011), The influence of micrometastases on prognosis and survival in stage I-II colon cancer patients: the Enroute circle plus Study, BMC Surgery 11: -.
- Nes, J.G.H. van; Kruijf, E.M. de; Putter, H.; Faratian, D.; Munro, A.; Campbell, F.; Smit, V.T.H.B.M.; Liefers, G.J.; Kuppen, P.J.K.; Velde, C.J.H. van de & Bartlett, J.M.S. (2011), Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients.
- Duijvestein, M.; Wildenberg, M.E.; Welling, M.M.; Hennink, S.; Molendijk, I.; Zuylen, V.L. van; Bosse, T.; Vos, A.C.W.; Jonge-Muller, E.S.M. de; Roelofs, H.; Weerd, L. van der; Verspaget, H.W.; Fibbe, W.E.; Velde, A.A.T.; Brink, G.R. van den & Hommes, D.W. (2011), Pretreatment with Interferon-gamma Enhances the Therapeutic Activity of Mesenchymal Stromal Cells in Animal Models of Colitis, STEM CELLS 29(10): 1549-1558.
- Nes, J.G.H. van; Kruijf, E.M. de; Faratian, D.; Velde, C.J.H. van de; Putter, H.; Falconer, C.; Smit, V.T.H.B.M.; Kay, C.; Vijver, M.J. van de; Kuppen, P.J.K. & Bartlett, J.M.S. (2011), COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients.
- Eijk, R. van; Licht, J.; Schrumpf, M.; Yazdi, M.T.; Ruano, D.; Forte, G.I.; Nederlof, P.M.; Veselic, M.; Rabe, K.F.; Annema, J.T.; Smit, V.; Morreau, H. & Wezel, T. van (2011), Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCR, PLoS ONE 6(3): -.
- Meijer, S.L.; Wesseling, J.; Smit, V.T.; Nederlof, P.M.; Hooijer, G.K.J.; Ruijter, H.; Arends, J.W.; Kliffen, M.; Gorp, J.M. van; Sterk, L. & Vijver, M.J. van de (2011), HER2 gene amplification in patients with breast cancer with equivocal IHC results, Journal of Clinical Pathology 64(12): 1069-1072.
- Kruijf, E.M. de; Nes, J.G.H. van; Velde, C.J.H.V. de; Putter, H.; Smit, V.T.H.B.M.; Liefers, G.J.; Kuppen, P.J.K.; Tollenaar, R.A.E.M. & Mesker, W.E. (2011), Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients.
- Staal, E.F.W.C.; Smit, V.T.H.B.M.; Velthuysen, M.L.F. van; Spitzer-Naaykens, J.M.J.; Wouters, M.W.J.M.; Mesker, W.E.; Tollenaar, R.A.E.M. & Sandick, J.W. van (2011), Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies, European Journal of Cancer 47(3): 375-382.
- Huijts, P.E.A.; Dongen, M. van; Goeij, M.C.M. de; Moolenbroek, A.J. van; Blanken, F.; Vreeswijk, M.P.G.; Kruijf, E.M. de; Mesker, W.E.; Zwet, E.W. van; Tollenaar, R.A.E.M.; Smit, V.T.H.B.M.; Asperen, C.J. van & Devilee, P. (2011), Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10, Breast Cancer Research 13(4): -.
- Broeks, A.; Schmidt, M.K.; Sherman, M.E.; Couch, F.J.; Hopper, J.L.; Dite, G.S.; Apicella, C.; Smith, L.D.; Hammet, F.; Southey, M.C.; Veer, L.J. van 't; Groot, R. de; Smit, V.T.H.B.M.; Fasching, P.A.; Beckmann, M.W.; Jud, S.; Ekici, A.B.; Hartmann, A.; Hein, A.; Schulz-Wendtland, R.; Burwinkel, B.; Marme, F.; Schneeweiss, A.; Sinn, H.P.; Sohn, C.; Tchatchou, S.; Bojesen, S.E.; Nordestgaard, B.G.; Flyger, H.; Orsted, D.D.; Kaur-Knudsen, D.; Milne, R.L.; Perez, J.I.A.; Zamora, P.; Rodriguez, P.M.; Benitez, J.; Brauch, H.; Justenhoven, C.; Ko, Y.D.; Hamann, U.; Fischer, H.P.; Bruning, T.; Pesch, B.; Chang-Claude, J.; Wang-Gohrke, S.; Bremer, M.; Karstens, J.H.; Hillemanns, P.; Dork, T.; Nevanlinna, H.A.; Heikkinen, T.; Heikkila, P.; Blomqvist, C.; Aittomaki, K.; Aaltonen, K.; Lindblom, A.; Margolin, S.; Mannermaa, A.; Kosma, V.M.; Kauppinen, J.M.; Kataja, V.; Auvinen, P.; Eskelinen, M.; Soini, Y.; Chenevix-Trench, G.; Spurdle, A.B.; Beesley, J.; Chen, X.Q.; Holland, H.; Lambrechts, D.; Claes, B.; Vandorpe, T.; Neven, P.; Wildiers, H.; Flesch-Janys, D.; Hein, R.; Loning, T.; Kosel, M.; Fredericksen, Z.S.; Wang, X.S.; Giles, G.G.; Baglietto, L.; Severi, G.; McLean, C.; Haiman, C.A.; Henderson, B.E.; Marchand, L. le; Kolonel, L.N.; Alnaes, G.G.; Kristensen, V.; Borresen-Dale, A.L.; Hunter, D.J.; Hankinson, S.E.; Andrulis, I.L.; Mulligan, A.M.; O'Malley, F.P.; Devilee, P.; Huijts, P.E.A.; Tollenaar, R.A.E.M.; Asperen, C.J. van; Seynaeve, C.S.; Chanock, S.J.; Lissowska, J.; Brinton, L.; Peplonska, B.; Figueroa, J.; Yang, X.H.R.; Hooning, M.J.; Hollestelle, A.; Oldenburg, R.A.; Jager, A.; Kriege, M.; Ozturk, B.; Leenders, G.J.L.H. van; Hall, P.; Czene, K.; Humphreys, K.; Liu, J.J.; Cox, A.; Connley, D.; Cramp, H.E.; Cross, S.S.; Balasubramanian, S.P.; Reed, M.W.R.; Dunning, A.M.; Easton, D.F.; Humphreys, M.K.; Caldas, C.; Blows, F.; Driver, K.; Provenzano, E.; Lubinski, J.; Jakubowska, A.; Huzarski, T.; Byrski, T.; Cybulski, C.; Gorski, B.; Gronwald, J.; Brennan, P.; Sangrajrang, S.; Gaborieau, V.; Shen, C.Y.; Hsiung, C.N.; Yu, J.C.; Chen, S.T.; Hsu, G.C.; Hou, M.F.; Huang, C.S.; Anton-Culver, H.; Ziogas, A.; Pharoah, P.D.P.; Garcia-Closas, M.; Genica Network; KConFab & AOCS (2011), Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium, Human Molecular Genetics 20(16): 3289-3303.
- Appelman-Dijkstra, N.M.; Pereira, A.M.; Smit, V.T.H.B.M. & Kapiteijn, E. (2011), Multifocal adrenal nerve tissue?
- Nout, R.A.; Smit, V.T.H.B.M.; Putter, H.; Juergenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Bunningen, B.N.F.M. van; Ansink, A.C.; Putten, W.L.J. van; Creutzberg, C.L. & PORTEC Study Grp (2010), Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial, Lancet 375(9717): 816-823.
- Staal, E.F.W.C.; Wouters, M.W.J.M.; Sandick, J.W. van; Takkenberg, M.M.; Smit, V.T.H.B.M.; Junggeburt, J.M.C.; Spitzer-Naaykens, J.M.J.; Karsten, T.; Hartgrink, H.H.; Mesker, W.E. & Tollenaar, R.A.E.M. (2010), The stromal part of adenocarcinomas of the oesophagus: Does it conceal targets for therapy?, European Journal of Cancer 46(4): 720-728.
- Graauw, M. de; Miltenburg, M.H. van; Schmidt, M.K.; Pont, C.; Lalai, R.; Kartopawiro, J.; Pardali, E.; Devedec, S.E. le; Smit, V.T.; Wal, A. van der; Van't Veer, L.J.; Cleton-Jansen, A.M.; Dijke, P. ten & Water, B. van de (2010), Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells, Proceedings of the National Academy of Sciences 107(14): 6340-6345.
- Kruijf, E.M. de; Sajet, A.; Nes, J.G.H. van; Natanov, R.; Putter, H.; Smit, V.T.H.B.M.; Liefers, G.J.; Elsen, P.J. van den; Velde, C.J.H. van de & Kuppen, P.J.K. (2010), HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients, Journal of Immunology 185(12): 7452-7459.
- Seeber, L.M.S.; Zweemer, R.P.; Marchionni, L.; Massuger, L.F.A.G.; Smit, V.T.H.B.M.; Baal, W.M. van; Verheijen, R.H.M. & Diest, P.J. van (2010), Methylation profiles of endometrioid and serous endometrial cancers, Endocrine-Related Cancer 17(3): 663-673.
- Kruijf, E.M. de; Sajet, A.; Nes, J.G.H. van; Natanov, R.; Putter, H.; Smit, V.T.H.B.M.; Liefers, G.J.; Eisen, P.J. van den; Velde, C.J.H. van de & Kuppen, P.J.K. (2010), HLA-E and HLA-G tumour expression is of prognostic value for clinical outcome of early breast cancer patients, but exclusively in classical HLA class I tumor-negative patients, EJC Supplements 8(3): 173-173.
- Nout, R.A.; Smit, V.T.H.B.M.; Putter, H.; Juergenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Bunningen, B.N.F.M. van; Ansink, A.C.; Putten, W.L.J. van; Creutzberg, C.L. & PORTEC Study Grp (2010), Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
- Seeber, L.; Zweemer, R.; Marchionni, L.; Massuger, L.; Smit, V.; Baal, M. van; Verheijen, R. & Diest, P. van (2010), METHYLATION PROFILES IN ENDOMETRIAL CANCER OF DIFFERENT HISTOLOGICAL SUBTYPES, Analytical Cellular Pathology / Cellular Oncology 32(3): 184-185.
- Nout, R.A.; Smit, V.T.H.B.M.; Putter, H.; Juergenliemk-Schulz, I.M.; Jobsen, J.J.; Lutgens, L.C.H.W.; Steen-Banasik, E.M. van der; Mens, J.W.M.; Slot, A.; Kroese, M.C.S.; Bunningen, B.N.F.M. van; Ansink, A.C.; Putten, W.L.J. van; Creutzberg, C.L. & PORTEC Study Grp (2010), Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
- Hutteman, M.; Choi, H.S.; Mieog, J.S.D.; Vorst, J.R. van der; Ashitate, Y.; Kuppen, P.J.K.; Groningen, M.C. van; Lowik, C.W.G.M.; Smit, V.T.H.B.M.; Velde, C.J.H. van de; Frangioni, J.V. & Vahrmeijer, A.L. (2010), Clinical Translation of Ex Vivo Sentinel Lymph Node Mapping for Colorectal Cancer Using Invisible Near-Infrared Fluorescence Light.
- Kruijf, E.M. de; Nes, J.G.H. van; Sajet, A.; Tummers, Q.R.J.G.; Putter, H.; Osanto, S.; Speetjens, F.M.; Smit, V.T.H.B.M.; Liefers, G.J.; Velde, C.J.H. van de & Kuppen, P.J.K. (2010), The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer, Clinical Cancer Research 16(4): 1272-1280.
- Ven, S. van de; Smit, V.T.H.B.M.; Dekker, T.J.A.; Nortier, J.W.R. & Kroep, J.R. (2010), Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer., Cancer Treatment Reviews.
- de Kruijf EM, van Nes JGH, van de Velde CH, Putter H, Smit VTHBM, Liefers GJ, Kuppen PK, Tollenaar RAEM & Mesker WE (2009), Tumor-Stroma Ratio within the Primary Tumor Is a Prognostic Factor in Early Breast Cancer Patients, Especially in Triple-Negative-Carcinoma Patients, Cancer Research 69(24): 661S662S.
- de Kruijf E, van Nes J, Sajet A, Putter H, Osanto S, Speetjens F, Smit V, Liefers GJ, van de Velde C & Kuppen P (2009), The predictive value of HLA Class I tumor cell expression and tumor infiltration by regulatory T cells for chemotherapy in patients with early breast cancer, EJC Supplements 7(4): 15-15.
- van Nes JGH, Smit VTHBM, Putter H, Kuppen PJ, Kim SJ, Daito M, Ding J, Shibayama M, Numada S & Gohda K (2009), Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients, British Journal of Cancer 100(3): 494-500.
- Nout RA, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS & van Bunningen BNFM (2009), Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial, Journal of Clinical Oncology 27(21): 3547-3556.
- Nout RA, Smit VTHB, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JM, Slot A & Creutzberg CL (2009), Vaginal Brachytherapy vs. External Beam Radiotherapy for High-intermediate Risk Endometrial Cancer: Results of the Randomized PORTEC-2 Trial after Central Pathology Review, International Journal of Radiation Oncology - Biology - Physics 75(3): S87S87.
- Cleton-Jansen, A.M.; Eijk, R. van; Lombaerts, M.; Schmidt, M.K.; Van't Veer, L.J.; Philippo, K.; Zimmerman, R.M.E.; Peterse, J.L.; Smit, V.T.B.H.M.; Wezel, T. van & Cornelisse, C.J. (2008), ATBFI and NQOI as candidate targets for allelic loss at chromosome arm 16q in breast cancer: Absence of somatic ATBFI mutations and no role for the C609T NQOI polymorphism, BMC Cancer 8.
- Hensen EF, De Herdt MJ, Goeman JJ, Oosting J, Smit VTHBM, Cornelisse CJ & de Jong RJB (2008), Gene-expression of metastasized versus non-metastasized primary head and neck squamous cell carcinomas: A pathway-based analysis, BMC Cancer 8.
- Wouters, M.; Takkenberg, M.; Mesker, W.; Smit, V.; Stassen, L.; Hartgrink, H. & Tollenaar, R. (2008), Tumour-stroma ratio: a strong and independent prognostic factor for adenocarcinomas of the esophagus, Annals of Surgical Oncology 15.
- van Nes JGH, Smit VTHBM, Putter H, Kuppen PJ, Kim SJ, Masuda N, Inaji H, Yoshidome K, Tsujimoto M, Akiyama F, Tsukamoto F, Ishihara H, Noguchi S & van de Velde CJH (2007), Cyclin-dependent kinase 1 and 2 activity as prognostic markers in early breast cancer, Breast Cancer Research and Treatment 106.
- Nagel HT, Vandenbussche FP, Smit VT, Wasser MN & Peters AA (2007), Intraplacental choriocarcinoma as an unexpected cause of intrauterine death at term, International Journal of Gynecological Cancer 17(6).
- Gooskens J, Templeton KE, Class EC, van Bussel MJ, Smit VT & Kroes AC (2007), Quantitative detection of herpes simplex virus DNA in the lower respiratory tract, Journal of Medical Virology 79(5).
- Schmidt, M.K.; Tollenaar, R.A.E.M.; Kemp, S.R. de; Broeks, A.; Cornelisse, C.J.; Smit, V.T.H.B.M.; Peterse, J.L.; Leeuwen, F.E. van & Van't Veer, L.J. (2007), Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation, Journal of Clinical Oncology 25(1).
- van Coppenraet LSB, Smit VTHBM, Templeton KE, Claas ECJ & Kuijper EJ (2007), Application of real-time PCR to recognize atypical mycobacteria in archival skin biopsies - High prevalence of Mycobacterium haemophilum, Diagnostic Molecular Pathology 16(2).
- van Nieuwkoop C, Gooskens J, Smit VTHBM, Claas ECJ, van Hogezand RA, Kroes ACM & Kroon FP (2007), Lymphogranuloma venereum proctocolitis: mucosal T cell immunity of the rectum associated with chlamydial clearance and clinical recovery, Gut 56(10).
- Bauer MP, Brouwer PA, Smit VTHBM & Tamsma JT (2007), The challenges of extrapulmonary presentations of sarcoidosis: A case report and review of diagnostic strategies, European Journal of Internal Medicine 18(2).
- Nout RA, Putter H, Schuitz IM, Jobsen JJ, Lutgens LCHM, van der Steen-Banasik EM, Mens JW, Slot A, Smit VT & Creutzberg CL (2007), Quality of life after radiotherapy for endometrial cancer: first results from the randomized PORTEC-2 trial, EJC Supplements 5(4).
- Scholten AN, Aliredjo R, Creutzberg CL & Smit VTHBM (2006), Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma, International Journal of Gynecological Cancer 16(3).
- Schmidt MK, Tollenaar RAEM, De Kemp S, Broeks A, Cornelisse CJ, Smit VTHBM, Van der plas A, De groot R, Peterse JL, Van't Veer LJ & Van Leeuwen FE (2006), Breast cancer survival and tumor characteristics of premenopausal women carrying the CHEK2*1100delC mutation, European Journal of Epidemiology 21: 107-107.
- Scholten AN, van Putten WLJ, Beerman H, Smit VTHBM, Koper PCM, Lybeert MLM, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KAJ, Lutgens LCHW, van Lent M & Creutzberg CL (2005), Postoperative radiotherapy for stage 1 endometrial carcinoma: Long-term outcome of the randomized PORTEC trial with central pathology review, International Journal of Radiation Oncology - Biology - Physics 63(3).
- Schmidt MK, van der Plas A, de Kemp SR, Klaver S, Nota B, Maertzdorf B, de Groot R, Udo R, Smit VTHBM, Broeks A, Peterse JL, van Leeuwen FE, Tollenaar RAEM & van't Veer LJ (2005), Genetic determinants of breast cancer characteristics and outcome in women under 50 years of age, Breast Cancer Research 7: S19S19.
- Voigt PG, Braun J, Teng OY, Koolbergen DR, Holman E, Bax JJ, Smit VTHBM & Dion RAE (2005), Double bioprosthetic valve replacement in right-sided carcinoid heart disease, Annals of Thoracic Surgery 79(6).
- Scholten AN, Smit VTHBM, Beerman H, van Putten WLJ & Creutzberg CL (2004), Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma, Cancer 100(4).
- Kuyvenhoven JP, Verspaget HW, Gao Q, Ringers J, Smit VTHBM, Lamers CBHW & Van Hoek B (2004), Assessment of serum matrix metalloproteinases MMP-2 and MMP-9 after human liver transplantation: Increased serum MMP-9 level in acute rejection, Transplantation 77(11).
- Koolbergen DR, Voigt P, Kolowca M, Smit VTHBM, Somer ST & Dion RA (2004), Elective surgery for fibroelastoma of the aortic valve, Annals of Thoracic Surgery 77(2).
- Lombaerts M, Middeldorp JW, van der Weide E, Philippo K, van Wezel T, Smit VTHBM, Cornelisse CJ & Cleton-Jansen AM (2004), Infiltrating leukocytes confound the detection of E-cadherin promoter methylation in tumors, Biochemical and Biophysical Research Communications 319(2).
- Buijs, J.T.; Cleton, A.M.; Smit, V.T.H.B.M.; Lowik, C.W.G.M.; Papapoulos, S.E. & Pluijm, G. van der (2004), Prognostic significance of periodic acid-Schiff-positive patterns in primary breast cancer and its lymph node metastases, Breast Cancer Research and Treatment 84(2).
- Cleton-Jansen AM, Buerger H, ter Haar N, Philippo K, van de Vijver MJ, Boecker W, Smit VTHBM & Cornelisse CJ (2004), Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer, Genes, Chromosomes and Cancer 41(2).
- Scholten AN, Creutzberg CL, van den Broek LJCM, Noordijk EM & Smit VTHBM (2003), Nuclear beta-catenin is a molecular feature of type 1 endometrial carcinoma, Journal of Pathology 201(3).
- Scholten AN, Creutzberg CL, Noordijk EM & Smit VTHBM (2002), Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system, International Journal of Radiation Oncology - Biology - Physics 52(4).
- van Roggen JFG & Smit VTHBM (2001), Hydatidiform mole., New England Journal of Medicine 345(7).
- Cleton-Jansen AM, Callen DF, Seshadri R, Goldup S, McCallum B, Crawford J, Powell JA, Settasatian C, van Beerendonk H, Moerland EW, Smit VTBHM, Harris WH, Millis R, Morgan NV, Barnes D, Mathew CG & Cornelisse CJ (2001), Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions, Cancer Research 61(3).
- Plaatsvervangend lid-beroepsgenoot